The consequences of estrogen deprivation and therapeutic interventions such as radiation, chemotherapy and surgery have a significant negative impact on libido, sexual arousal, orgasmic function and the ability to have pleasurable intercourse. Evaluation and treatment of female sexual dysfunction is a significant unmet need in the breast cancer survivor in spite of the availability of safe and effective treatments.
Keywords: DHEA; Dyspareunia; Female sexual dysfunction; Fractional CO2 laser; Genitourinary syndrome of menopause; Hypoactive sexual desire disorder; Ospemifene; Prasterone; Vaginal estrogen.